My watch list  


Systematic (IUPAC) name
3-methyl-2- [pentanoyl-[ [4-[2-(2H-tetrazol-5-yl) phenyl] phenyl] methyl]amino] -butanoic acid
CAS number 137862-53-4
ATC code C09CA03
PubChem 60846
DrugBank APRD00133
Chemical data
Formula C24H29N5O3 
Mol. mass 435.519 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 95%
Metabolism  ?
Half life 6 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status

Prescription only

Routes oral

Valsartan is an angiotensin II receptor antagonist, acting on the AT1 subtype. In the U.S., valsartan is indicated for treatment of high blood pressure, of congestive heart failure (CHF), and post-myocardial infarction (MI). It is marketed by Novartis under the trade name Diovan®. In 2005, Diovan® was prescribed more than 12 million times in the United States. A study released by the Journal of Clinical Investigation in 2007 found some efficacy in the use of Valsartan in the treatment and prevention of Alzheimer's Disease although such use is considered to be highly experimental.[1]


Oral tablets, containing 40 mg (scored), 80 mg, 160 mg or 320 mg of valsartan. Usual dosage ranges from 40–320 mg daily.

In some markets available as a Hard Gelatin Capsule, containing 40mg, 80mg, or 160mg of valsartan.

Diovan HCT® contains a combination of Valsartan and hydrochlorothiazide but, unlike Diovan®, is only indicated for hypertension, not for CHF or post-MI.

Side effects

Most commonly, headache and dizziness.


  1. ^ "Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease." . 2007.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Valsartan". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE